Document Detail

A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients.
MedLine Citation:
PMID:  22850565     Owner:  NLM     Status:  Publisher    
PURPOSE: Imatinib minimal (trough) plasma concentrations after 1 month of treatment have shown a significant association with clinical benefit in patients with gastrointestinal stromal tumors (GIST). Considering a retrospective pharmacokinetic (PK) analysis has also suggested that imatinib clearance increases over time in soft tissue sarcoma and GIST patients, the primary aim of this study was to assess systemic exposure to imatinib at multiple time points in a long-term prospective population PK study. As imatinib is mainly metabolized in the liver, our secondary aim was to elucidate the potential effects of the volume of liver metastases on exposure to imatinib. EXPERIMENTAL DESIGN: Full PK blood sampling was performed in 50 GIST patients on the first day of imatinib treatment, and after 1, 6 and 12 months. Additionally, on day 14, and monthly during imatinib treatment, trough samples were taken. PK analysis was performed using a compartmental model. Volume of liver metastases was assessed by CT imaging. RESULTS: After 90 days of treatment, a significant decrease in imatinib systemic exposure of 29.3% compared to baseline was observed (P less than 0.01). For every 100 cm3 increase of metastatic volume, a predicted decrease of 3.8% in imatinib clearance was observed. CONCLUSIONS: This is the first prospective PK study in GIST patients, demonstrating a significant decrease of approximately 30% in imatinib exposure after long-term treatment. This means that future 'trough level - clinical benefit' analyses should be time-point specific. GIST liver involvement however has a marginal effect on imatinib clearance.
Karel Eechoute; Martin N Fransson; An K L Reyners; Floris A de Jong; Alex Sparreboom; Winette T A van der Graaf; Lena E Friberg; Gaia Schiavon; Erik Ac Wiemer; Jaap Verweij; Walter J Loos; Ron H J Mathijssen; Ugo De Giorgi
Related Documents :
826225 - Tuberculous peritonitis: 43 years' expereince in diagnosis and treatment.
22544225 - Efficacy of microwave versus radiofrequency ablation for treatment of small hepatocellu...
2031975 - Neutropenic enterocolitis following treatment with cytosine arabinoside-containing regi...
1680465 - Comparison of severity of acquired renal cysts between capd and hemodialysis.
15596675 - The influence of type 2 diabetes mellitus in patients undergoing coronary artery bypass...
12027195 - A novel approach to the prevention of postoperative delirium in the elderly after gastr...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-7-31
Journal Detail:
Title:  Clinical cancer research : an official journal of the American Association for Cancer Research     Volume:  -     ISSN:  1078-0432     ISO Abbreviation:  Clin. Cancer Res.     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-8-1     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9502500     Medline TA:  Clin Cancer Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Medical Oncology, Erasmus University Medical Center - Daniel den Hoed Cancer Center.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Peripheral (limb) myokymic discharges in motor neuron disease.
Next Document:  The rectal cancer microRNAome - microRNA expression in rectal cancer and matched normal mucosa.